Citizens lowers Mirum Pharmaceuticals price target on valuation
ArchivedSingle Source|2 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Citizens Investment Research cut the price target for Mirum Pharmaceuticals on February 26, 2026.
- •The price target reduction was based on valuation concerns rather than company earnings.
- •On the same day, Citizens raised the price target for LeMaitre Vascular following an earnings beat.
- •Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases.
What Could Happen If...
- ▸If Mirum Pharmaceuticals improves its financial outlook or product pipeline investor confidence could increase, potentially raising the stock price and reversing the price target cut impact.
Market Exposure
StocksMirum PharmaceuticalsDownward Pressure
The price target cut by Citizens on valuation concerns may lead investors to sell or avoid the stock, putting downward pressure on its price.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Source Coverage
FINANCE
2 articles
More coverage on this story
- More on LeMaitre Vascular stock
- More on Mirum Pharmaceuticals stock
- More on Citizens Investment Research
- More on LeMaitre Vascular
Signals
Single-block coverage
Related Events
▸Citizens maintains Summit Therapeutics rating on pipeline growthArchived▸Citizens maintains outperform rating on LeMaitre Vascular stockArchived▸Lattice Semiconductor stock price target raised to $110 from $80 at StifelArchived▸Stifel raises Tandem Diabetes stock price target after revenue beatArchived▸H.C. Wainwright lowers Evommune price target over dilution concerns